Cti tracker

The Contraceptive Technology Innovation Tracker—CTI Tracker—houses information on potential contraceptive leads in early development, products in pre-clinical and clinical development, and products with single-country regulatory approval. The Tracker reports on both active development platforms and inactive R&D.

Contraceptive Pipeline Baseline Report ⬇ Export Database

For more information about contraceptive R&D, visit our partner databases

Show Filters
Inactive
Last updated: May 29, 2025
Nonwoven Vaginal MPT
  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Vaginal - Other
  • Intended Duration: Pericoital
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): FHI 360, RTI International, University of the Witwatersrand
Inactive
Last updated: May 29, 2025
Desogestrel + Testosterone Oral Contraceptive
  • User: Male
  • Hormonal: Hormonal
  • Delivery Type: Oral
  • Intended Duration: Undetermined
  • Development Stage: Phase I
  • Developer(s)/Researcher(s): University of Edinburgh, University of Washington
Inactive
Last updated: May 29, 2025
BioRing MPT IVR

Cornell Vaginal Ring

  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Vaginal Ring
  • Intended Duration: Undetermined
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): BioRings, Weill Cornell Medicine
Inactive
Last updated: May 29, 2025
Cinchonine Derivatives

3-(1-alkyl/aminoalkyl-3-vinyl-piperidin-4-yl)-1-(quinolin-4-yl)-propan-1-one, Quinine

  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Vaginal Gel
  • Intended Duration: Pericoital
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): Central Drug Research Institute, Lucknow; University of Lagos
Inactive
Last updated: May 29, 2025
Biosynthetic Calcium Injectable Implant

"Inject and Forget" Contraceptive Drug Delivery Device

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Subdermal
  • Intended Duration: Undetermined
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): Murdoch University
Inactive
Last updated: April 17, 2025
Lower-Dose DMPA

Depo-Provera 45 mg, Depo-Provera 75 mg

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Injectable
  • Intended Duration: Short-Acting
  • Development Stage: Phase I
  • Developer(s)/Researcher(s): FHI 360
Inactive
Last updated: April 9, 2025
Vaginal Tablet with Adhesive Microcapsules
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Vaginal - Other
  • Intended Duration: Short-Acting
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): University of Texas Health Science Center at San Antonio, University of Oslo, University of Tromso
Inactive
Last updated: April 9, 2025
UPA Vaginal Ring
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Vaginal Ring
  • Intended Duration: Short-Acting
  • Development Stage: Phase II
  • Developer(s)/Researcher(s): Population Council, HRA Pharma
Inactive
Last updated: April 9, 2025
Uniplant
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Subdermal
  • Intended Duration: Long-Acting
  • Development Stage: Phase III
  • Developer(s)/Researcher(s): Population Council, Theramex, University of Bahia
Inactive
Last updated: April 9, 2025
TU + ENG

Testosterone Undecanoate (TU) + Etonogestrel (ENG)

  • User: Male
  • Hormonal: Hormonal
  • Delivery Type: Multiple
  • Intended Duration: Short-Acting
  • Development Stage: Phase II
  • Developer(s)/Researcher(s): Organon